Agios Shares Plunge 25% After Novo Data

Agios Pharmaceuticals shares plunged 25% on Monday after Novo Nordisk announced positive sickle cell trial data.
Novo’s etavopivat showed a 27% reduction in vaso‑occlusive crises and delayed first crisis by about four months versus standard care.
Agios is pursuing FDA accelerated approval for its own sickle‑cell candidate mitapivat, while analysts note the impact is largely priced in.
Analysts Gregory Renza (Truist) and James Condulis (Stifel) maintain buy rating but warn the competitor’s success pressures Agios’s pipeline.